See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Holi
Social Media
Artificial Intelligence
European Union
Trade War
Donald Trump
Vladimir Putin
Stock Markets
Tariffs
Education
Formula 1
Published • loading... • Updated

Treating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research identifies novel mechanism

Summary by Medical Xpress
Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and hepatocellular carcinoma. While fibroblast growth factor 21 (FGF21) analogs have shown promise in clinical trials, their underlying molecular mechanisms remain unclear.

1 Articles

All
Left
Center
Right
Medical XpressMedical Xpress

Treating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research identifies novel mechanism

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and hepatocellular carcinoma. While fibroblast growth factor 21 (FGF21) analogs have shown promise in clinical trials, their underlying molecular mechanisms remain unclear.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medical Xpress broke the news in on Tuesday, February 18, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Research

Research

Medical

Medical

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal